Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). [electronic resource]
Producer: 20190318Description: 118-125 p. digitalISSN:- 1365-2893
- Adult
- Aged
- Anilides -- administration & dosage
- Antiviral Agents -- administration & dosage
- Carbamates -- administration & dosage
- Cyclopropanes
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- genetics
- Hepatitis C -- drug therapy
- Humans
- Lactams, Macrocyclic
- Liver Cirrhosis -- drug therapy
- Macrocyclic Compounds -- administration & dosage
- Male
- Middle Aged
- Proline -- analogs & derivatives
- RNA, Viral -- blood
- Ribavirin -- administration & dosage
- Ritonavir -- administration & dosage
- Sofosbuvir -- administration & dosage
- Sulfonamides
- Sustained Virologic Response
- Treatment Outcome
- Valine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.